Cevostamab Biosimilar - Anti-FCRL5;CD3 mAb - Research Grade
Species
Bispecific mAb
Expression system
XtenCHO
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Cevostamab,,FCRL5;CD3,anti-FCRL5;CD3
Reference
PX-TA1823
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1 Kappa;IgG1 Kappa
Clonality
Monoclonal Antibody
Description of Cevostamab Biosimilar - Anti-FCRL5;CD3 mAb - Research Grade
Introduction
Cevostamab Biosimilar, also known as Anti-FCRL5,CD3 mAb, is a novel antibody that has been developed as a potential therapeutic agent for various diseases. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in detail.
Structure of Cevostamab Biosimilar
Cevostamab Biosimilar is a monoclonal antibody that is composed of two different types of proteins: the Fc region and the Fab region. The Fc region is responsible for the effector functions of the antibody, while the Fab region binds to the target antigen.
The Fc region of Cevostamab Biosimilar is derived from human IgG1, which is known to have a longer half-life in the body compared to other antibody isotypes. This allows for a prolonged therapeutic effect of the antibody. The Fab region is composed of two heavy chains and two light chains, which are responsible for binding to the target antigen.
Activity of Cevostamab Biosimilar
The main activity of Cevostamab Biosimilar is its ability to bind to FCRL5, a protein that is highly expressed on the surface of certain immune cells, such as B cells and T cells. By binding to FCRL5, Cevostamab Biosimilar can modulate the immune response and potentially treat various diseases.
In addition to its ability to bind to FCRL5, Cevostamab Biosimilar also has a CD3 binding domain. CD3 is a protein found on the surface of T cells and is involved in T cell activation. By binding to CD3, Cevostamab Biosimilar can activate T cells and enhance their immune response.
Therapeutic Applications of Cevostamab Biosimilar
Cevostamab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including autoimmune disorders, cancer, and infectious diseases.
Autoimmune Disorders
FCRL5 has been found to be overexpressed on B cells in patients with autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus. By targeting FCRL5, Cevostamab Biosimilar can potentially modulate the immune response and treat these diseases.
Cancer
FCRL5 is also highly expressed on the surface of cancer cells, making it a potential therapeutic target for cancer treatment. By binding to FCRL5, Cevostamab Biosimilar can potentially induce cell death in cancer cells and inhibit tumor growth.
Infectious Diseases Cevostamab Biosimilar has also shown potential in treating
infectious diseases, such as viral infections. By activating T cells through its CD3 binding domain, Cevostamab Biosimilar can enhance the immune response and potentially clear viral infections.
Conclusion
Cevostamab Biosimilar, also known as Anti-FCRL5,CD3 mAb, is a novel antibody with the potential to treat various diseases. Its unique structure and dual activity make it a promising therapeutic agent for autoimmune disorders, cancer, and infectious diseases. Further clinical studies are needed to fully evaluate the efficacy and safety of this biosimilar, but early results are promising.
Reviews
There are no reviews yet.